3 episodes

Insider Insights: 100 Days of Biden is a podcast from the law firm Buchanan Ingersoll & Rooney. Each episode, the firm's government relations professionals and attorneys will offer insights on expected legislative and regulatory changes during President Joe Biden’s first 100 days in office.

Insider Insights: 100 Days of Bide‪n‬ Buchanan Ingersoll & Rooney

    • Government
    • 5.0 • 2 Ratings

Insider Insights: 100 Days of Biden is a podcast from the law firm Buchanan Ingersoll & Rooney. Each episode, the firm's government relations professionals and attorneys will offer insights on expected legislative and regulatory changes during President Joe Biden’s first 100 days in office.

    Healthcare – What does the Road to the Public Option Look Like?

    Healthcare – What does the Road to the Public Option Look Like?

    President Joe Biden proposed building on the Affordable Care Act (Obamacare) as his main healthcare goal by, among other things, introducing a public option. What does this mean for healthcare providers and insurers, and what steps will be taken in his first 100 days? What will the Department of Health and Human Services (HHS) look like if President Biden’s selection for HHS secretary, current California AG Xavier Becerra, is confirmed?

    In the third episode of Insider Insights: 100 Days of Biden, Mike Strazzella, practice group leader of Buchanan’s federal government relations practice and co-head of the firm’s D.C. office, and Bob Ramsey, co-chair of Buchanan’s healthcare industry group, discuss some of the biggest issues the White House faces to improve healthcare in the U.S.

    In this episode, Mike and Bob cover:

    - The biggest differences between President Biden’s views on healthcare and former President Trump’s

    - What President Biden can do to reform healthcare via the Oval Office and Executive Orders and what will require the help of the House and the Senate

    - What HHS might look like if Xavier Becerra is confirmed as secretary

    - What’s included in President Biden’s executive order signed in January claiming to strengthen Medicaid and the Affordable Care Act, and how it impacts payors and providers

    - Predictions for the Supreme Court’s ruling on the constitutionality of the Affordable Care Act, an opinion the Biden administration changed from his predecessor Donald Trump

    - What, if anything, can be done to change or improve healthcare legislation via budget reconciliation and what will require full votes from Congress

    To find out more about Buchanan's experience in the healthcare industry, visit: https://www.bipc.com/healthcare.

    To watch a recording of the Congressional Process Master Class Webinar Series on budget reconciliation that Mike mentions, visit: https://www.bipc.com/congressional-process-master-class-webinar-series-session-two.

    For info on Buchanan’s capabilities in Government Relations, visit: https://www.bipc.com/government-relations-and-public-policy

    To read more about Mike Strazzella, visit: https://www.bipc.com/michael-strazzella.

    To read more about Bob Ramsey, visit: https://www.bipc.com/robert-ramsey.

    And finally, head to www.BIPC.com to learn more about Buchanan Ingersoll & Rooney.

    • 15 min
    Infrastructure – Does Biden’s Path to Bipartisanship Start with Infrastructure?

    Infrastructure – Does Biden’s Path to Bipartisanship Start with Infrastructure?

    As a candidate, Joe Biden promised he would prioritize rebuilding America’s middle class and often that starts with job creation to build critical infrastructure. Are there significant achievements in infrastructure policy Biden can enact in his first 100 days? What does former presidential candidate and South Bend, Indiana, mayor Pete Buttigieg’s appointment to Secretary of Transportation mean for the industry? What role can companies have in shaping that policy? How will the president’s vision for a greener future for American energy impact infrastructure, at least initially?

    In the second episode of Insider Insights: 100 Days of Biden, Jim Wiltraut and Terry Heubert, Principals in Buchanan Ingersoll & Rooney’s Government Relations Practice Group, dive into what President Biden’s first 100 days will look like for those businesses and organizations that occupy the transportation and infrastructure sectors.

    As part of this episode, Terry and Jim cover:

    - Chair of the Committee on Transportation and Infrastructure Peter DeFazio’s plan for infrastructure and whether it can be an early bipartisan win for the Biden administration

    - Pete Buttigieg’s qualifications for Secretary of Transportation and what the department may look like under his lead

    - If and how private business can influence legislation in transportation and infrastructure in President Joe Biden’s first 100 days

    - Congressional earmarks, whether they return under a democrat-led congress, whether that’s a good idea and how it gets done

    - COVID-19’s impact on infrastructure and transportation, especially as it relates to airports and airlines

    To find out more about Buchanan's experience in the transportation space, visit: https://www.bipc.com/transportation.

    For info on Buchanan’s capabilities in Government Relations, visit: https://www.bipc.com/government-relations-and-public-policy

    To read more about Jim Wiltraut, visit: https://www.bipc.com/james-wiltraut.

    To read more about Terry Heubert, visit: https://www.bipc.com/terrence-heubert.

    And finally, head to www.BIPC.com to learn more about Buchanan Ingersoll & Rooney.

    • 15 min
    Life Sciences – COVID-19 Vaccine Safety, Drug Pricing Reform, and Beyond

    Life Sciences – COVID-19 Vaccine Safety, Drug Pricing Reform, and Beyond

    In the life sciences industry, all eyes will continue to be on a successful COVID-19 vaccine rollout and when it can be safely administered to enough of the population to return to normal life. If all goes as planned, what other challenges will face the industry under this new administration? How will life sciences companies need to evolve? How will capping drug prices, allowing Medicare to negotiate prices, and drug importation affect competition and growth in the industry?

    In the first episode of Insider Insights: 100 Days of Biden, Barbara Binzak Blumenfeld, a life sciences shareholder with Buchanan Ingersoll & Rooney with a specific focus on FDA regulation, serves as host. She interviews Liz Westbrook a senior advisor from Buchanan's federal government relations team in Washington, DC. Liz focuses on analyzing prospective laws and regulations in the life sciences space and beyond.

    As part of this episode, Barbara and Liz cover:

    - Expectations for the Biden administration with distributing the COVID-19 vaccine

    - What other topics and focuses the new FDA will have under President Biden

    - How price capping, allowing Medicare to negotiate prices, and drug importation will affect competition and growth in the industry

    - The names floated to lead key life sciences regulatory bodies, including HHS, FDA and more

    - Actions to expect the Department of Health and Human Services to take on under the Biden administration

    In the episode, Barbara also brings up an important side topic as part of the COVID-19 vaccine -- whether companies can mandate that their employees take the vaccine. Here's the client advisory she wrote on that topic: https://www.bipc.com/the-vaccine-mandate-what-healthcare-employers-need-to-know-about-mandating-the-covid-19-vaccine. 

    To find out more about Buchanan's Life Sciences capabilities, visit: https://www.bipc.com/life-sciences. 

    To read more about Barbara, visit: https://www.bipc.com/barbara-binzak-blumenfeld.

    To read more about Liz, visit: https://www.bipc.com/elizabeth-westbrook.

    And finally, head to www.BIPC.com to learn more about Buchanan Ingersoll & Rooney. 

    • 16 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Government